Apixaban Dose for DVT Prophylaxis
For DVT prophylaxis after major orthopedic surgery (hip or knee replacement), use apixaban 2.5 mg orally twice daily, starting 12-24 hours after surgery, for 35 days after hip replacement and 12 days after knee replacement. 1
Major Orthopedic Surgery (Hip and Knee Replacement)
The FDA-approved dosing regimen is straightforward and well-established:
- Dose: 2.5 mg orally twice daily
- Initiation: 12-24 hours after wound closure
- Duration:
- Hip replacement: 35 days
- Knee replacement: 12 days 1
This regimen demonstrated superior efficacy compared to enoxaparin 40 mg once daily in the ADVANCE-2 and ADVANCE-3 trials. In hip arthroplasty, apixaban reduced VTE from 3.9% to 1.4% (RR 0.36,95% CI 0.22-0.54, P<0.001), and in knee arthroplasty from 24.4% to 15.1% (RR 0.62,95% CI 0.51-0.78, P<0.0001) 2, 3. Importantly, bleeding rates were numerically lower with apixaban in all trials 2.
The most recent 2025 guidelines confirm apixaban 2.5 mg twice daily as an approved indication for VTE prevention post hip and knee replacements 3. The 2026 ACC statement supports that both DOACs and LMWH are appropriate for VTE prophylaxis post-THA or TKA, with DOACs preferred due to easier logistics and potentially better cost-effectiveness 4.
Important Contraindications and Precautions
Do not use apixaban if:
- Creatinine clearance < 25 mL/min 3
- Severe liver disease (Child-Pugh C) 3
- Concomitant use of potent CYP3A4 inhibitors (ketoconazole, ritonavir) 2
Medically Ill Patients
For acutely ill medical patients, apixaban is NOT recommended for extended thromboprophylaxis. 2
The ADOPT trial evaluated apixaban 2.5 mg twice daily for 30 days versus enoxaparin 40 mg once daily for 6-14 days in hospitalized acutely ill medical patients. The results were disappointing:
- Efficacy: No superiority over shorter enoxaparin course (2.71% vs 3.06%, RR 0.87,95% CI 0.62-1.23)
- Safety: Significantly increased major bleeding (0.47% vs 0.19%, RR 2.58,95% CI 1.02-7.24, P<0.04) 2
Therefore, extended thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin and was associated with more bleeding 2. Standard LMWH remains the preferred option for medically ill patients requiring VTE prophylaxis.
Clinical Pearls
- No dose adjustment needed for age, gender, or body weight in the orthopedic surgery setting 2
- No bridging required when interrupting apixaban for procedures 5, 1
- Renal function monitoring is essential—apixaban has 27% renal elimination 2, 3
- For missed doses, take as soon as possible on the same day; do not double the dose 1
The evidence strongly supports apixaban 2.5 mg twice daily as an effective and safe option for VTE prophylaxis after hip and knee replacement, with a favorable risk-benefit profile compared to traditional LMWH regimens. However, its use in medically ill patients should be avoided due to increased bleeding risk without additional efficacy benefit.